logo

Sangamo Biosciences Inc (SGMO)



Trade SGMO now with
  Date
  Headline
8/12/2019 7:37:51 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Rev. Estimate To 16.9 M From 30.2 M
8/12/2019 7:36:25 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) FY20 Estimate To -1.34 From -1.17
8/12/2019 7:36:06 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 20 Estimate To -0.38 From -0.33
8/12/2019 7:35:58 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 20 Estimate To -0.38 From -0.33
8/12/2019 7:35:35 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) Q2 20 Estimate To -0.37 From -0.33
8/12/2019 7:35:21 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q1 20 Estimate To -0.21 From -0.17
8/12/2019 7:35:02 AM Wedbush Is Lowering Sangamo Biosciences Inc (SGMO) FY19 Estimate To -1.20 From -0.92
8/12/2019 7:34:48 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q4 19 Estimate To -0.26 From -0.17
8/12/2019 7:34:35 AM Wedbush Is Cutting Sangamo Biosciences Inc (SGMO) Q3 19 Estimate To -0.28 From -0.18
8/12/2019 7:33:35 AM Wedbush Reiterates Sangamo Biosciences Inc (SGMO) At Neutral With $11 Price Target
5/8/2019 4:03:07 PM Sangamo Therapeutics Q1 Loss/share $0.41 Vs. Loss $0.23 Year Ago
4/4/2019 8:05:04 AM Sangamo Therapeutics Prices Public Offering Of 11 Mln Shares At $11.50 Per Share
4/3/2019 4:02:45 PM Sangamo Therapeutics Announces Proposed Public Offering Of Common Stock
4/2/2019 7:05:59 AM Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
4/2/2019 7:01:56 AM Sangamo, Pfizer Announce Interim Data From Phase 1/2 Alta Study On SB-525 Gene Therapy For Severe Hemophilia A
3/29/2019 7:08:54 AM Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression
3/8/2019 5:03:26 AM Sangamo Reports Publication Of Data Showing New Zinc Finger Nuclease Architectures Enabling Genome Editing